Erratum: Erratum for Garcia et al., Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression [Molecular and Cellular Biology, 34, 11, (2014), (2017-2028)] Doi: 10.1128/MCB.00090-14;Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression

Molecular and Cellular Biology

Volumn 34, Issue 11, 2014, Pages 2017-2028

  Garcia, Alejandro J ^a   Ruscetti, Marcus ^a,c   Arenzana, Teresita L ^a   Tran, Linh M ^a   Bianci Frias, Daniella ^b   Sybert, Elysia ^a   Priceman, Saul J ^a   Wu, Lily ^a   Nelson, Peter S ^b   Smale, Stehen T ^a   Wu, Hong ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL EXPANSION; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE CONTROL; IMMUNOREGULATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SUPPRESSOR CELL; T LYMPHOCYTE;

ANIMALS; ANISOLES; ANTIGENS, CD11B; ARGINASE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITHELIUM; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKIN-1BETA; LYMPHOCYTE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, TRANSGENIC; MYELOID CELLS; NITRIC OXIDE SYNTHASE TYPE II; PROSTATE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES; UP-REGULATION;

EID: 84899817878     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00886-14     Document Type: Erratum

References (47)

1. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51. http://dx.doi.org/10.1016/j.cell.2010.03.014.
2. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140:883-899. http://dx.doi.org/10.1016/j.cell.2010.01.025.
3. Chow A, Brown BD, Merad M. 2011. Studying the mononuclear phagocyte system in the molecular age. Nat. Rev. Immunol. 11:788-798. http://dx.doi.org/10.1038/nri3087.
4. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983. http://www.jimmunol.org/content/179/2/977.long.
5. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. 2012. Crosstalk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22:275-281. http://dx.doi.org/10.1016/j.semcancer.2012.01.011.
6. Mantovani M, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436-444. http://dx.doi.org/10.1038/nature 07205.
7. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:678-689. http://www.jimmunol.org/content/16 6/1/678.long.
8. Serafini P, MgebroffS, Noonan K, Borrello I. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439-5449. http://dx.doi.org/10.1158/0008-5472.CAN-07-6621.
9. Li H, Han Y, Guo Q, Zhang M, Cao X. 2009. Cancer-expanded myeloidderived suppressor cells induce anergy of NK cells through membranebound TGF-beta 1. J. Immunol. 182:240-249. http://www.jimmunol.org/content/182/1/240.long.
10. Sfanos KS, De Marzo AM. 2012. Prostate cancer and inflammation: the evidence. Histopathology 60:199-215. http://dx.doi.org/10.1111/j.1365-2559.2011.04033.x.
11. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. 2004. The role of inflammation in the pathogenesis of prostate cancer. J. Urol. 172:S6-S11; discussion S11-S12. http://dx.doi.org/10.1097/01.ju.0000142058.99614.ff
12. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu C, Wu H. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221. http://dx.doi.org/10.1016/S1535-6108(03)00215-0.
13. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS. 2010. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 5:e12501. http://dx.doi.org/10.1371/journal.pone.0012501.
14. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. 2007. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 67:6083-6091. http://dx.doi.org/10.1158/0008-5472.CAN -06-4202.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102.
16. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57:289-300.
17. Ilkovitch D, Lopez DM. 2009. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 69:5514-5521. http://dx.doi.org/10.1158/0008-5472.CAN -08-4625.
18. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG. 2008. Phenotypic analysis of prostateinfiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14:3254-3261. http://dx.doi.org/10.1158/1078-0432.CCR-07-5164.
19. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid- derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802. http://www.jimmunol.org/content/181/8/5791.long.
20. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22. http://dx.doi.org/10.1016/j.ccr.2010.05.026.
21. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63:4441-4449. http://cancerres.aacrjournals.org/content/63/15/4441.long.
22. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L. 2010. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115:1461-1471. http://dx.doi.org/10.1182/blood-2009-08-237412.
23. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. 1998. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778-4791.
24. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D. 2004. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64:5378-5384. http://dx.doi.org/10.1158/0008-5472.CAN-04-0961.
25. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727-740. http://dx.doi.org/10.1084/jem.193.6.727.
26. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA. 2010. IL-1beta regulates a novel myeloidderived suppressor cell subset that impairsNKcell development and function. Eur. J. Immunol. 40:3347-3357. http://dx.doi.org/10.1002/eji.201041037.
27. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC. 2008. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419. http://dx.doi.org/10.1016/j.ccr.2008.10.011.
28. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN. 2005. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1betasecreting cells. J. Immunol. 175:8200-8208. http://www.jimmunol.org/content/175/12/8200.long.
29. Condamine T, Gabrilovich DI. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19-25. http://dx.doi.org/10.1016/j.it.2010.10.002.
30. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:270-278. http://www.jimmunol.org/content/170/1/270.long.
31. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253-268. http://dx.doi.org/10.1038/nri3175.
32. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. 2004. Arginases I and II: do their functions overlap? Mol. Genet. Metab. 81(Suppl 1):S38-S44. http://dx.doi.org/10.1016/j.ymgme.2003.10.012.
33. Chen DS, Mellman I. 2013. Oncology meets immunology: the cancerimmunity cycle. Immunity 39:1-10. http://dx.doi.org/10.1016/j.immuni.2013.07.012.
34. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. 2011. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand. J. Gastroenterol. 46:156-164. http://dx.doi.org/10.3109/00365521.2010.516450.
35. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196:541-549. http://dx.doi.org/10.1084/jem.20020732.
36. Tagliani E, Shi C, Nancy P, Tay CS, Pamer EG, Erlebacher A. 2011. Coordinate regulation of tissue macrophage and dendritic cell population dynamics by CSF-1. J. Exp. Med. 208:1901-1916. http://dx.doi.org/10.1084/jem.20110866.
37. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT. 2005. Inhibition of colony-stimulatingfactor- 1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. U. S. A. 102:16078-16083. http://dx.doi.org/10.1073/pnas.0502000102.
38. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26:127-132. http://dx.doi.org/10.1038/nbt1358.
39. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE. 2010. Myeloid-derived suppressor cells in mammarytumor progression inFVBNeutransgenic mice. Cancer Immunol. Immunother. 59:47-62. http://dx.doi.org/10.1007/s00262-009-0719-2.
40. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. 2009. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 9:937-948. http://dx.doi.org/10.1016/j.intimp.2009.03.021.
41. Patsialou A, WyckoffJ, Wang Y, Goswami S, Stanley ER, Condeelis JS. 2009. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res. 69:9498-9506. http://dx.doi.org/10.1158/0008-5472.CAN-09-1868.
42. Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1:54-67. http://dx.doi.org/10.1158/2159-8274.CD -10-0028.
43. Balkwill F, Mantovani A. 2001. Inflammation and cancer: back to Virchow? Lancet 357:539-545. http://dx.doi.org/10.1016/S0140-6736(00) 04046-0.
44. Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, RatliffTL. 2011. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate 71: 1139-1150. http://dx.doi.org/10.1002/pros.21327.
45. Kusmartsev SA, Li Y, Chen SH. 2000. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165:779-785. http://www.jimmunol.org/content/165/2/779.long.
46. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. 2006. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24:3089-3094. http://dx.doi.org/10.1200/JCO.2005.04.5252.
47. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. 2009. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679. http://dx.doi.org/10.1002/cncr.24429.